Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Accumulated Expenses (2017 - 2026)

Intellia Therapeutics has reported Other Accumulated Expenses over the past 12 years, most recently at $8.1 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 167.72% to $8.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Mar 2026, up 167.72% year-over-year, with the annual reading at $17.4 million for FY2025, 737.72% up from the prior year.
  • Other Accumulated Expenses was $8.1 million for Q1 2026 at Intellia Therapeutics, down from $17.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $30.3 million in Q3 2022 and troughed at $2.1 million in Q4 2024.
  • The 5-year median for Other Accumulated Expenses is $8.1 million (2026), against an average of $12.3 million.
  • Year-over-year, Other Accumulated Expenses surged 1179.88% in 2022 and then crashed 92.44% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $5.0 million in 2022, then surged by 452.98% to $27.4 million in 2023, then crashed by 92.44% to $2.1 million in 2024, then soared by 737.72% to $17.4 million in 2025, then crashed by 53.33% to $8.1 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Other Accumulated Expenses are $8.1 million (Q1 2026), $17.4 million (Q4 2025), and $15.7 million (Q3 2025).